Abstract
Transurethral ethanol ablation of the prostate (TEAP) has emerged among the treatment alternatives to transurethral resection of prostate as a promising minimally invasive therapy that can be performed on an outpatient basis with fewer complications. It was introduced approximately 5 years ago, and to date, 12-month results are encouraging. We herein review the procedure and outcomes of TEAP.
Get full access to this article
View all access options for this article.